The giant pharmaceuticals company operating in India, the GlaxoSmithKline Pharmaceuticals (GSKP) has made an official announcement on Wednesday and said that it has recently signed an agreement with the Japan-based Astellas Pharma. The official statement of the company has informed that the pact has been signed for getting exclusive rights for Astellas injectible anti-fungal agent in the Indian market and the agent is the micafungin with a brand name Mycamine.
The Managing Director of GSK India, Mr. Hasit Joshipura was talking about the matter and said, "One of our growth plans is to partner with global pharmaceutical companies for licensing in important molecules. The agreement with Astellas is in line with our strategy". He informed that the company is hoping that the micafungin is going to strengthen its presence in the intensive care segment and it is also going to provide an excellent fit with oncology, where GSK is having a promising R&D pipeline.
|
|
|
|
|
| Posted : 5/15/2008 |
|
|
|
|
